• Drugs Made in America Acquisition II updated compensation terms tied to CFO services under Titan Advisory Services on April 22, 2026.
• Monthly CFO fee remained $3,500, with unpaid amounts continuing to accrue as obligations.
• Saleem Elmasri became entitled to 175,000 ordinary shares, up from 100,000 previously contemplated, to be issued at closing of initial business combination within 10 days.
• Company also set CEO compensation for Roger E. Bendelac at $4,500 per month, with $2,500 payable currently and up to $2,000 deferrable based on cash flow.
• Aleutian Equity Holdings, as designated vehicle for Bendelac, became entitled to 250,000 ordinary shares to be issued at closing of initial business combination within 10 days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-048687), on April 28, 2026, and is solely responsible for the information contained therein.